• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A membrane-based purification process for cell culture-derived influenza A virus

tetano

Editor, Senior Moderator
J Biotechnol. 2015 Dec 19. pii: S0168-1656(15)30221-2. doi: 10.1016/j.jbiotec.2015.12.022. [Epub ahead of print]
[h=1]A membrane-based purification process for cell culture-derived influenza A virus.[/h] Weigel T[SUP]1[/SUP], Solomaier T[SUP]2[/SUP], Wehmeyer S[SUP]3[/SUP], Peuker A[SUP]4[/SUP], Wolff MW[SUP]5[/SUP], Reichl U[SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] A simple membrane-based purification process for cell culture-derived influenza virus was established that relies on only two chromatographic unit operations to achieve the contamination limits required according to regulatory authorities. After clarification and concentration, a pseudo-affinity membrane adsorber (sulfated cellulose, SCMA) was applied for virus capture. The subsequent polishing step consisted of a salt-tolerant anion exchange membrane adsorber (STMA) to bind residual DNA. For the presented process neither a buffer exchange step nor a nuclease step for further DNA digestion were required. As a starting point, a two-salt strategy (including a polyvalent ion) was employed to screen STMA conditions in a 96-well plate format. After optimization on chromatographic laboratory scale, the virus recovery was up to 97% with a residual DNA level below 0.82%. In addition, the STMA was characterized regarding its dynamic binding capacity and the impact of flow rate on yields and contamination levels. Overall, the total virus yield for influenza virus A/PR/8/34 (H1/N1) of this two-step membrane process was 75%, while the protein and the DNA contamination level could be reduced to 24% and at least 0.5%, respectively. With 19.8μg protein and 1.2ng DNA per monovalent dose, this purity level complies with the limits of the European Pharmacopeia for cell culture-derived vaccines for human use. Overall, the presented downstream process might serve as a generic and economic platform technology for production of cell culture-derived viruses and viral vectors.
Copyright ? 2015. Published by Elsevier B.V.


[h=4]KEYWORDS:[/h] Downstream process; Influenza virus vaccine purification process; Primary amine anion exchange membrane; Pseudo-affinity membrane chromatography; Salt-tolerant membrane chromatography; Sulfated cellulose membrane adsorber

PMID: 26712479 [PubMed - as supplied by publisher]
 
Back
Top Bottom